Mirum Pharmaceuticals Inc. - notizie pubblicate 221 - letture 2.973
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer mirum pharmaceutical ...
MIRUM PHARMACEUTICALS INC.
Material Definitive Agreement - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Quarterly Report (Form 10-Q)
10-q united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ac ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer mirum pharmaceuticals inc. publish ...
MIRUM PHARMACEUTICALS INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer mirum pharmaceuticals inc. publish ...
MIRUM PHARMACEUTICALS INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer mirum pharmaceuticals inc. publish ...
MIRUM PHARMACEUTICALS INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer mirum pharmaceuticals inc. publish ...
MIRUM PHARMACEUTICALS INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer mirum pharmaceuticals inc. publish ...
MIRUM PHARMACEUTICALS INC.
Insider Trading Report (SEC Filing - 4)
The text version of this document is not available. you can access the original document here. attachments original document permalink disclaimer mirum pharmaceuticals inc. publish ...
MIRUM PHARMACEUTICALS INC.
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older (Form 8-K)
U.s. fda approves livmarli (maralixibat) as the first and only approved medication for the treatment of cholestatic pruritus in patients with alagille syndrome one year of age and ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti